EASL Podcasts

This EASL Studio episode explores how alcohol worsens liver disease in patients with cardiometabolic risks, the stigma affecting diagnosis and care, and the latest therapeutic advances.Key topics of discussion include:Interaction between alcohol and cardiometabolic risksStigma and its impact on patient careIdentifying at-risk patients with clinical markersEmerging therapies and research opportunitiesFacultyAleksander Krag (Moderator)Fredrik Åberg (Faculty)Maru Rinella (Faculty)Maja Thiele (Faculty)This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.Related episodesEASL Studio S5E9: Alcohol and the new nomenclature – A game-changer?EASL Studio S4E8: The central role of alcohol and food policies on liver healthEASL Studio S4E3: A 360 approach to beat alcohol-related liver diseaseEASL Studio S3E5: JHEP Live: Stigma and alcoholAll EASL Studio Podcasts are available on EASL Campus.

Join the experts as they explore the new updates to the liver transplantation clinical practice guidelines, and delve into the latest advancement and ongoing challenges faced in this field.Tune in to:Discover cutting-edge techniques like machine perfusion and extended criteria grafts.Learn about new transplant indications, including oncology and acute liver failure.Understand challenges in immunosuppression and the management of chronic rejection.FacultyAhmed Elsharkawy (Moderator)Didier Samuel (Faculty)Julie Heimbach (Faculty)Sarwa Darwish (Faculty)Related episodesEASL Studio S4E13: JHEP Live: Liver transplantation for alcohol-related hepatitisEASL Studio S4E6: Regenerating the liver graft with a machineEASL Studio S3E2: Liver transplantation for ACLF: Opportunities, challenges, and pitfallsEASL Studio S3E8: Transplanting patients with cancer – Is there a limit?All EASL Studio Podcasts are available on EASL Campus.

This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition.FacultyJeffrey Lazarus (Moderator)Mazen Noureddin (Faculty)Shira Zelber-Sagi (Faculty)Kremlin Wickramasinghe (Faculty)The Healthy Livers, Healthy Lives Coalition’s activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk.Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition’s activities or this EASL Studio episode.Related episodesEASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio S6E7: The impact of policy measure in preventing liver diseases: The Hepahealth II studyEASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio S4 Special Edition 2: Promoting Liver Health: An urgent call for action at WHOEASL Studio S4E8: The central role of alcohol and food policies on liver healthAll EASL Studio Podcasts are available on EASL Campus.

This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:Compares traditional ultrasound with advanced imaging techniques.Examines AI-based approaches in patient classification.The episode concludes with a forward-looking perspective on the future management of MASLD.FacultyThomas Berg (Moderator)Timm Denecke (Faculty)Juan-Manuel Pericàs (Faculty)Valérie Vilgrain (Faculty)This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.Related episodesEASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceAll EASL Studio Podcasts are available on EASL Campus.

Renal dysfunction is a significant concern for patients with liver cirrhosis, affecting nearly 50% of those hospitalised and leading to various complications that can reduce survival rates. Recently, the diagnostic criteria for acute kidney injury (AKI) and hepatorenal syndrome (HRS) have been updated to better capture the diversity and incidence of these conditions in cirrhotic patients.This episode of EASL Studio:Explores the updated definitions and standardisation of AKI in the context of cirrhosis.Reviews recent clinical trials, including ATTIRE and CONFIRM, and their implications for patient care.Provides a critical analysis of current and emerging strategies for managing renal dysfunction in cirrhosis.FacultyDebbie Shawcross (Moderator)Pere Gines (Faculty)Salvatore Piano (Faculty)Florence Wong (Faculty)Related episodesEASL Studio from EASL Congress 2024: Deciphering the drivers of cirrhosis decompensation: Opportunities for intervention and preventionEASL Studio S6E8: Is there a role for measuring blood ammonia in patients with cirrhosis?EASL Studio S6E5: JHEP Live: Should the compensated advanced chronic liver disease (cACLD) concept replace cirrhosis?EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address themEASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?This episode is sponsored by Mallinckrodt Pharmaceuticals. Mallinckrodt Pharmaceuticals have had no input into the content of this EASL Studio episode.All EASL Studio Podcasts are available on EASL Campus.

Arrivederci Milano, hallo Amsterdam!FacultyAleksander Krag (Moderator)Debbie Shawcross (Moderator)Cyrielle Caussy (Faculty)Ana Lleo (Faculty)Francesco Negro (Faculty)Vlad Ratziu (Faculty)Virginia Hernández-Gea (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Education at the heart of EASL’s missionFacultySven Francque (Moderator)Krista Rombouts (Faculty)Rajeshwar Mookerjee (Faculty)Henning Grønbæk (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Landmark studies at the EASL Congress 2024FacultyThomas Berg (Moderator)Rajiv Jalan (Faculty)Verena Keitel (Faculty)Frank Tacke (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - SLD nomenclature: Need for refinement?FacultyAleksander Krag (Moderator)Meena Bansal (Faculty)Sven Francque (Faculty)Alexandre Louvet (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Exploring new frontiers: The AI liver taskforce initiativeFacultyEric Trépo (Moderator)Tom Lüdde (Faculty)Jakob Kather (Faculty)Raquel Pérez-López (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Advances in systemic treatments in liver cancerFacultyJosep Llovet (Moderator)Massimo Iavarone (Faculty)Matthias Pinter (Faculty)Jessica Zucman-Rossi (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Buongiorno Milano: What not to miss during EASL Congress.FacultyAleksander Krag (Moderator)Debbie Shawcross (Faculty)Thomas Berg (Faculty)Ahmed Elsharkawy (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This session covers a wide range of topics relevant to the current landscape of viral hepatitis, including elimination efforts, resistance to direct-acting antivirals (DAAs), surveillance methods during and after therapy. This talk provides you with valuable insights through an up-to-date overview of the latest developments and challenges in the field.FacultyThomas Berg (Moderator)Jordan Feld (Faculty)Norah Terrault (Faculty)Heiner Wedemeyer (Faculty)This episode is scheduled in honour of the United States’ Viral Hepatitis Awareness Month.This EASL Studio is supported by GSK and Vir Biotechnology. EASL has received no input from GSK or Vir Biotechnology with regards to the content of this programme.Related episodesSeason 6, Episode 2: Why do we need HBV functional cure?Season 5, Episode 8: JHEP Live: Hepatitis Delta’s Latest Debate: Updates Straight from EASL’s SlateSeason 5, Episode 3: Zoonotic Hepatitis E: What’s hot in 2023?EASL Studio at the EASL Congress 2023: The bumpy road of Hepatitis B drug development successes and challengesSeason 4, Episode 19: HDV: The devil becomes treatableSeason 4, Episode 1: Hepatitis B elimination: how far behind are we and what do we need to change to achieve it?All EASL Studio Podcasts are available on EASL Campus.

This insightful discussion is centred on the burgeoning field of endohepatology, where advanced endoscopic techniques revolutionise hepatology practice. With this episode, explore the broad scope of endoscopic procedures (including EUS-guided liver biopsy, portal pressure measurement, and gastric varices embolisation) and their transformative impact on diagnostics and therapeutic interventions in liver disease.To learn even more about endoscopic procedures in hepatology, take a look at this study by Wim Laleman et al., published in January 2024 in the Journal of Hepatology.Faculty Wim Laleman (Moderator)Andres Cardenas (Faculty)Gavin Johnson (Faculty)Reem Sharaiha (Faculty)Related episodesSeason 6, Episode 11: Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?Season 3, Episode 15: Chronic portal vein thrombosis: anticoagulation and interventional radiology for all patients?Season 2, Episode 14: Elastography – The new non-invasive gold standard in portal hypertension?All EASL Studio Podcasts are available on EASL Campus.

This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.FacultyAleksander Krag (Moderator)Naim Alkhouri (Faculty)Sven Francque (Faculty)Amalia Gastaldelli (Faculty)Related episodesSeason 5 , Episode 2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureSeason 4, Episode 23: The Conundrum of NASH: The Growing Global Disease Burden with Low Disease AwarenessSeason 4, Episode 22: JHEP Live: New and promising drugs for NASH on the horizonAll EASL Studio Podcasts are available on EASL Campus.

Join us for a critical discussion on the significance of Drug and Herbal & Dietary Supplement-Induced Liver Injury (DHILI). In this episode, the speakers explore the importance of DHILI, assess recent advancements, and deliberate on the obstacles hindering further progress in addressing this pressing healthcare concern.This episode is organised in collaboration with the EASL DHILI Consortium.FacultyGuruprasad Padur Aithal (Moderator)Paul Hayashi (Faculty)Maribel Lucena (Faculty)Paul Watkins (Faculty)Related episodesSeason 4, Episode 20 – COST Actions: opportunities for pan-European collaborations in liver diseasesAll EASL Studio Podcasts are available on EASL Campus.

In this episode, experts explore the shift away from invasive measurements in assessing clinically significant portal hypertension. The speakers address the crucial data needed to enhance the reliability and applicability of these non-invasive methods and introduce several advanced elastography techniques, shaping the future of portal hypertension assessment.FacultyBogdan Procopet (Moderator)Maria Papp (Faculty)Atoosa Rabiee (Faculty)Thomas Reiberger (Faculty)Related episodeEASL Studio S2E14: Elastography – The new non-invasive gold standard in portal hypertension?All EASL Studio Podcasts are available on EASL Campus.

This episode aims at highlighting the importance of patient and public involvement in research. More precisely, the speakers focus on the importance of involving patients in research, practical steps to involve patients in research, and insights from EASL including engagement of patients in the EASL-Lancet Commission.FacultyMarta Alonso-Peña (Moderator)Kate Jack (Faculty)Marko Korenjak (Faculty)Thomas Marjot (Faculty)Related episodeEASL Studio from EASL Congress 2023: United we stand: Global societies collaborating to beat liver disease.All EASL Studio Podcasts are available on EASL Campus.

This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm.FacultyBruno Sangro (Moderator)Umberto Cillo (Faculty) Helen Reeves (Faculty)María Reig (Faculty)This EASL Studio is supported by AstraZeneca. EASL has received no input from AstraZeneca with regards to the content of this programme.Related episodesEASL Studio S5E13: Basics in decision-making for liver cancer treatmentEASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillanceEASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlookEASL Studio S3E8: Transplanting patients with cancer – Is there a limit?EASL Studio S2E15: JHEP Live on the best animal model for HCC – Lost in translation?All EASL Studio Podcasts are available on EASL Campus.

In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.FacultyDebbie Shawcross (Moderator)Rajiv Jalan (Faculty)Sara Montagnese (Faculty)Elliot Tapper (Faculty)This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).Related episodesEASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address themEASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies withinEASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?EASL Studio S2E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?All EASL Studio Podcasts are available on EASL Campus.